Ftse Mib
36.200,72
0,24%
DAX
21.394,93
-0,11%
S&P 500
6.101,24
-0,29%
NASDAQ
19.954,30
-0,50%
Bitcoin
104.933,59
0,07%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX Palatin Technologies Inc New (PTN) Palatin Technologies Inc New (PTN) Notizie

PTN

Palatin Technologies (PTN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:PTN
DataOraFonteTitoloSimboloCompagnia
19/12/202413:30PR Newswire (US)Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic NephropathyAMEX:PTNPalatin Technologies Inc New
16/12/202415:25Edgar (US Regulatory)Form 8-K - Current reportAMEX:PTNPalatin Technologies Inc New
16/12/202413:30PR Newswire (US)Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross ProceedsAMEX:PTNPalatin Technologies Inc New
25/11/202413:30PR Newswire (US)Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative ColitisAMEX:PTNPalatin Technologies Inc New
14/11/202415:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:PTNPalatin Technologies Inc New
14/11/202413:30PR Newswire (US)Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial ResultsAMEX:PTNPalatin Technologies Inc New
08/11/202415:57PR Newswire (US)Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024AMEX:PTNPalatin Technologies Inc New
04/11/202413:30PR Newswire (US)Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024AMEX:PTNPalatin Technologies Inc New
31/10/202412:30PR Newswire (US)Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of ObesityAMEX:PTNPalatin Technologies Inc New
30/10/202414:07Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]AMEX:PTNPalatin Technologies Inc New
30/10/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:PTNPalatin Technologies Inc New
24/10/202413:30PR Newswire (US)Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics SymposiumAMEX:PTNPalatin Technologies Inc New
23/10/202413:30PR Newswire (US)Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics SymposiumAMEX:PTNPalatin Technologies Inc New
22/10/202422:31Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]AMEX:PTNPalatin Technologies Inc New
07/10/202422:15PR Newswire (US)Palatin Receives Notice of Non-Compliance from NYSE AmericanAMEX:PTNPalatin Technologies Inc New
01/10/202413:30PR Newswire (US)Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated MilestonesAMEX:PTNPalatin Technologies Inc New
30/09/202422:31Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]AMEX:PTNPalatin Technologies Inc New
26/09/202413:30PR Newswire (US)Palatin to Report Fourth Quarter and Fiscal Year End 2024 ResultsAMEX:PTNPalatin Technologies Inc New
09/09/202413:30PR Newswire (US)Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated MilestonesAMEX:PTNPalatin Technologies Inc New
28/08/202413:30PR Newswire (US)FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)AMEX:PTNPalatin Technologies Inc New
22/08/202413:30PR Newswire (US)First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of ObesityAMEX:PTNPalatin Technologies Inc New
02/08/202423:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
25/07/202422:46Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933AMEX:PTNPalatin Technologies Inc New
17/07/202417:14Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]AMEX:PTNPalatin Technologies Inc New
21/06/202414:00PR Newswire (US)Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross ProceedsAMEX:PTNPalatin Technologies Inc New
20/06/202413:30PR Newswire (US)Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)AMEX:PTNPalatin Technologies Inc New
12/06/202413:30PR Newswire (US)Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of ObesityAMEX:PTNPalatin Technologies Inc New
15/05/202413:30PR Newswire (US)Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateAMEX:PTNPalatin Technologies Inc New
09/05/202413:30PR Newswire (US)Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024AMEX:PTNPalatin Technologies Inc New
02/05/202413:30PR Newswire (US)Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of ObesityAMEX:PTNPalatin Technologies Inc New
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:PTN

La tua Cronologia

BIT
BMPS
Banca Monte Dei Paschi D...
BIT
UCG
Unicredit
BIT
MB
Mediobanca Banca di Cred...
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
ENEL
Enel
BIT
CPR
Davide Campari
BIT
BAMI
Banco BPM
BIT
MONC
Moncler
BIT
SPM
Saipem
BIT
STMMI
ST Microelectronics
BIT
BPE
Bper Banca
BIT
RACE
Ferrari NV
BIT
IVG
Iveco Group NV
BIT
G
Generali
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network